Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 65

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Pyoderma gangrenosum

Not recruiting

Study on Vilobelimab and Drug Combination for Treating Ulcerative Pyoderma Gangrenosum in Adults

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Betamethasone
  • Sponsor:InflaRx GmbH

Oral lichen planus+1

Not recruiting

Study on the Effectiveness of Deucravacitinib for Patients with Lichen Planus

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Dermatitis atopic

Not recruiting

Study on the Effect of a New Moisturiser with Glycerol and Urea on Skin Barrier in Adults with Atopic Dermatitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glycerol
  • Sponsor:Aco Hud Nordic AB

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of SAR441566 for Adults with Moderate to Severe Plaque Psoriasis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:SAR441566
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Chronic spontaneous urticaria

Not recruiting

Study on the Effects of Briquilimab in Adults with Chronic Spontaneous Urticaria Unresponsive to Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Urticaria chronic

Not recruiting

Study on Briquilimab for Adults with Chronic Inducible Urticaria Unresponsive to H1-Antihistamines

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Vitiligo

Not recruiting

Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:MK-6194
  • Sponsor:Merck Sharp & Dohme LLC

Chronic spontaneous urticaria

Not recruiting

Study on the Effects of EP262 for Adults with Chronic Spontaneous Urticaria

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:EP262
  • Sponsor:Escient Pharmaceuticals Inc.

Hyperhidrosis

Not recruiting

Study on the Effects of Tiotropium Bromide Gel for Patients with Severe Hand Sweating

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tiotropium Bromide Monohydrate
  • Sponsor:Dryox Health S.L.

Tuberous sclerosis complex+1

Not recruiting

Study on Radiprodil for Seizures and Behavioral Symptoms in Patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Radiprodil
  • Sponsor:Grin Therapeutics Inc.

Malignant melanoma

Not recruiting

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.